In this presentation, Dr. Zhoumeng Lin introduces how we develop physiologically based pharmacokinetic (PBPK) models of drugs, environmental chemicals and nanoparticles for applications in nanomedicine, food safety, and human health risk assessments. He presents his recent studies to illustrate each application. Dr. Zhoumeng Linalso introduces a new physiological parameter database for PBPK modeling in food-producing animals, including cattle, swine, sheep, …
The Need for Increased Maturity in the Risk Assessment Ecosystem
by Dr. Jean Orelien Last year, the US EPA declared they would phase away from animal testing by 2035. Reaching this milestone will require the maturity of the risk assessment ecosystem. By maturity, I mean new roles need to be assumed along with improved interactions and (stronger) bonds within and between group as well as new entities. In this post, I share a …
Physiologically Based Pharmacokinetic (PBPK) Modeling of Central Nervous System
by Marjory Moreau, Ph.D. I have worked in PBPK modeling for many years and until a few months ago, I never had to deal with the brain compartment. Well, I had a brain compartment in several of my models, but I never really thought about the blood brain barrier and all the transporters involved in protecting or bringing compounds into the brain until recently. I …
What are NAMs?
by Sage Corzine If you got pumped up about NAMs in a toxicology webinar, tried to find more information on Google, and got redirected to the North American Menopause Society, you are not alone. NAMs or New Approach Methodologies are a vital and growing part of chemical hazard and risk assessment research. Here are a few fun facts …
The Frontier of Aerosol Safety Testing with In Vitro and in Silico Methods
by Scott Slattery In May and June of this year, the annual Webinar Series on Inhalation Toxicity Testing was co-hosted by The US EPA, the PETA Science Consortium International, Syngenta, and Unilever. The nine webinars presented over three days provided an excellent look at current progress in the area of non-animal inhalation toxicity testing approaches. The talks covered the breadth of the field, addressing in …
Why ScitoVation is Part of my Journey
Dr. Jean Orelien, CEO My passion is helping solve problems at the intersection of health, science, and technology. In other words, problems for which we can use science and technology to improve lives. With ScitoVation, our long-term vision is to achieve this by helping our clients develop safe chemicals for humans and the environment using innovative science and technology. There are parallels between our work at ScitoVation and SciMetrika, the first company I founded in 2004 and sold in 2018. At SciMetrika, we used …